Osteoprotegerin Rabbit polyclonal Antibody IgG
Fig1: Western blot analysis of Osteoprotegerin on 293 (1) and K562 (2) cell lysate using anti-Osteoprotegerin antibody at 1/5,000 dilution.
Fig2: ICC staining Osteoprotegerin in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Fig3: Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti-Osteoprotegerin antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityRabbit; Human, Mouse, Rat
Application SummaryWB, ICC, IHC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesTumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin
BackgroundBone morphogenesis and remodeling involve the formation of bone from osteoblasts and the resorption of bone by osteoclasts. The cytokine osteoprotegerin (OPG), also designated osteoclastogenesis inhibitory factor (OCIF), is known to inhibit osteoclast formation. A secreted glycoprotein, OPG is a member of the TNF receptor family that increases bone density and volume. OPG is thought to inhibit osteoclastogenesis by disrupting the cell-to-cell signaling between osteoblastic stromal cells and osteoclast progenitors. OPG is known to bind to TRAIL, a death domain-containing protein, and to inhibit TRAIL apoptosis in Jurkat cells. OPG also binds to osteoclast differentiation factor (ODF), also known as TRANCE/RANKL, a membrane-bound protein belonging to the TNF ligand family. Both TNFα and TNFβ upregulate OPG expression, while the bone resorbing agent prostaglandin E2 downregulates OPG.(R1608-4)